Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Shares Issued (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Shares Issued for 14 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 431.39% year-over-year to -$1.5 million, compared with a TTM value of $18.2 million through Dec 2025, up 7644.4%, and an annual FY2025 reading of $18.3 million, up 2773.94% over the prior year.
  • Shares Issued was -$1.5 million for Q4 2025 at Heron Therapeutics, down from $19.3 million in the prior quarter.
  • Across five years, Shares Issued topped out at $19.3 million in Q3 2025 and bottomed at -$1.5 million in Q4 2025.
  • Average Shares Issued over 5 years is $2.5 million, with a median of $628000.0 recorded in 2021.
  • The sharpest move saw Shares Issued skyrocketed 29333.33% in 2021, then plummeted 431.39% in 2025.
  • Year by year, Shares Issued stood at $610000.0 in 2021, then grew by 10.16% to $672000.0 in 2022, then plummeted by 204.61% to -$703000.0 in 2023, then skyrocketed by 165.72% to $462000.0 in 2024, then tumbled by 431.39% to -$1.5 million in 2025.
  • Business Quant data shows Shares Issued for HRTX at -$1.5 million in Q4 2025, $19.3 million in Q3 2025, and $462000.0 in Q4 2024.